SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant volatility following a major seven billion dollar equity and equity-linked offering intended to fund approximately thirty-nine billion dollars in new AI server orders. While management cites the capital raise as a necessary step to secure components and scale for massive demand, the community remains deeply divided, with many investors concerned about share dilution and the stock's long-term reliance on frequent financing versus organic growth.

Cracker Barrel Old Country Store, Inc. engages in the operation and development of restaurant and retail outlets. The format of its stores consists of a trademarked rustic old country-store design that offers restaurant menu featuring home-style country food. The company was founded by Dan W. Evins on September 19, 1969 and is headquartered in Lebanon, TN.

Cracker Barrel Old Country Store Inc

Cracker Barrel is seeing heightened volatility and intense debate among investors as market participants weigh a major Q3 earnings beat and raised guidance against concerns over long-term foot traffic and debt. While some traders are capitalizing on the stock's surge and aggressive short squeeze potential, others remain skeptical, focusing on declining revenue and the company's ongoing efforts to execute a turnaround.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to strong May volume metrics for its Predictions platform, while the community remains divided between optimism over the product's growth potential and frustration regarding the stock's long-term performance. Sentiment is heavily polarized, with many retail traders debating whether prediction markets provide a durable competitive advantage or are merely a speculative distraction from core sports betting operations.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is trending as volatility in the energy sector intensifies following heightened tensions in the Strait of Hormuz, with market participants debating whether the geopolitical risk premiums are sustainable or if looming supply increases will lead to a correction. The community is actively parsing conflicting signals between official ceasefire reports and reports of naval confrontations, leaving traders divided on whether to buy the dip or hedge against a potential pullback in crude oil prices.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as it records over $7 billion in special charges to restructure its EV portfolio and China operations, joining industry peers in a strategic pullback from electric vehicle manufacturing. Investors are focused on the company's financial flexibility, including its recent dividend hike and stock buyback program, while debating the long-term impact of pivoting resources back toward high-margin trucks and SUVs.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors debate the potential impact of upcoming federal rescheduling hearings against the company's aggressive pivot toward an alcohol-focused strategy. The community remains deeply polarized, with many expressing significant frustration over ongoing dilution and share price volatility while others highlight the potential for long-term growth through global infrastructure and beverage expansion.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav shares are drawing significant attention as investors speculate on the timing of a potential FCC Notice of Proposed Rulemaking (NPRM) for the company's spectrum assets. While the community remains divided over short-term volatility and legislative noise, bullish participants are actively discussing the long-term value of the 900MHz spectrum and the potential for a national security-driven catalyst.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors debate the impact of AI on its infrastructure, with sentiment split between excitement over its role as a backbone for autonomous AI agents and anxiety regarding workforce restructuring. The community is actively weighing the potential for long-term growth against short-term margin pressures and the evolving threat landscape in the cybersecurity sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing investor attention following positive Phase 1 data for its subcutaneous Briumvi treatment in Myasthenia Gravis, which supports the potential for a broader addressable market. The stock remains a focal point for the community due to persistent buyout speculation and active discussions regarding the drug's competitive advantage over existing MS therapies.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing intense investor interest as the market prepares for a significant PDUFA decision on April 30 for the potential label expansion of Auvelity into Alzheimer's disease agitation. The community is actively discussing the drug's breakthrough therapy designation, the lack of effective alternatives for this condition, and the expectation that a successful approval could serve as a major catalyst for long-term growth and potential M&A activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged tosubmit their information immediately. You may also...

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.read more...

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations PR Newswire NEW YORK, June 3, 2026 SEC filings reflected...

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? 

Equity

The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology. 


Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) PR...

FULC Stock Crashes After Hours: What Investors Need To Know

Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.read more...

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk 

Fulcrum discontinued development of its lead candidate, pociredir, for sickle cell disease. 


After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Current Price	$3.52
Prev Close	$3.44
Open	$3.49
Dividend Yield	0.00%
50-Day Moving Average	$6.87
Beta	1.35
Avg. Volume	508,375.75
PE Ratio	-3.00

52-Week High	$15.74
52-Week Low	$2.83
Market Capitalization	$229.22M
EPS (Annual)	-$1.18
Price to Book	0.69
Revenue Per Employee	$0.00

FULCFulcrum Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FULC News